News - Cerezyme

Filter

Current filters:

Cerezyme

Popular Filters

Elelyso: a new therapeutic option for patients with Gaucher disease

09-05-2012

The US Food and Drug Administration recently approved Protalix BioTherapeutic's (NYSE-AMEX: OLX) Elelyso…

CerezymeElelysoGenzymeMarkets & MarketingPfizerPharmaceuticalProtalix BioTherapeuticsRare diseasesShireVpriv

GSK inks $300m rare diseases alliance with Angiochem

28-02-2012

GlaxoSmithKline has forged an R&D alliance with Montreal, Canada-based Angiochem that will focus on the…

AngiochemCerezymeGenzymeGSKNeurologicalPharmaceuticalRare diseasesShireVpriv

Ongoing supply problems for Genzyme’s Cerezyme

19-09-2011

US biotech Genzyme, now a subsidiary of French drug major Sanofi (Euronext: SAN), says it will have only…

BiotechnologyCerezymeFabrazymeGenzymeMarkets & MarketingPharmaceuticalRare diseasesSanofiShire

Shire says Fabry and Gaucher disease studies continue to support patient switches to Replagal and Vpriv

01-09-2011

Ireland-headquartered specialty drug firm Shire (LSE: SHP) reported positive data from several studies…

CerezymeFabrazymeGenzymePharmaceuticalRare diseasesReplagalResearchSanofiShireVpriv

Company Spotlight

Fibrotech

Fibrotech

Back to top